Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Tine Thurison Soerensen, PhD

    TitlePostdoctoral Scholar
    SchoolUCSF School of Pharmacy
    DepartmentPharmaceutical Chemistry
    Address600 16th Street
    San Francisco CA 94158
    Phone415-476-8147
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California San FranciscoPost docPharm Chem, Craik Lab2015
      University of CopenhagenPost docThe Finsen Laboratory/BRIC, Ploug Lab2015
      University of CopenhagenPh.DFaculty of Health Sciences2014
      Copenhagen University HospitalResearch assistantThe Finsen Laboratory, Hoyer-Hansen Lab2010
      University of CopenhagenM.Sc.Faculty of Health Sciences2009
      Collapse Awards and Honors
      The Danish Cancer Society2012 - 2014Independent Junior Research Grant

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Featured Publications

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Thurison T, Almholt K, Gårdsvoll H, Ploug M, Høyer-Hansen G, Lund IK. Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer. Mol Carcinog. 2016 May; 55(5):717-31. PMID: 25809119.
        View in: PubMed
      2. Thurison T, Christensen IJ, Lund IK, Nielsen HJ, Høyer-Hansen G. Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points. Clin Chim Acta. 2015 Jan 15; 439:84-90. PMID: 25305537.
        View in: PubMed
      3. Illemann M, Laerum OD, Hasselby JP, Thurison T, Høyer-Hansen G, Nielsen HJ, Christensen IJ. Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer. Cancer Med. 2014 Aug; 3(4):855-64. PMID: 24889870; PMCID: PMC4303153.
      4. Grunnet M, Christensen IJ, Lassen U, Jensen LH, Lydolph M, Lund IK, Thurison T, Høyer-Hansen G, Mau-Sørensen M. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. Clin Biochem. 2014 May; 47(7-8):599-604. PMID: 24530340.
        View in: PubMed
      5. Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets. 2011 Nov; 12(12):1744-60. PMID: 21707477.
        View in: PubMed
      6. Thurison T, Lomholt AF, Rasch MG, Lund IK, Nielsen HJ, Christensen IJ, Høyer-Hansen G. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin Chem. 2010 Oct; 56(10):1636-40. PMID: 20802096.
        View in: PubMed
      7. Olson FJ, Thurison T, Ryndel M, Høyer-Hansen G, Fagerberg B. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem. 2010 Jan; 43(1-2):124-30. PMID: 19822140.
        View in: PubMed
      Tine Thurison's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP